GlassScriptPhysician profile
Richard E Uhler
NPI 1205938537
$3,951.82
in general payments reported to CMS, 2019-2025
37 companies · $87.26 in 2025
The $87.26 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $183 · 2021: $456 · 2022: $2,342 · 2023: $326 · 2024: $109 · 2025: $87.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $2,014.40 | 2022 | |
| Abbvie INC. | $366.99 | 2019-2023 | Ubrelvy, Botox |
| Glaxosmithkline, LLC. | $270.18 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $183.43 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $104.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $102.74 | 2021-2022 | |
| Lilly USA, LLC | $93.01 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Merck Sharp & Dohme LLC | $79.44 | 2019-2022 | |
| Allergan, INC. | $72.73 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.48 | 2023 | Quviviq |
| Quidel Corporation | $41.61 | 2019 | |
| Nevro Corp. | $38.28 | 2019 | |
| Aytu Biopharma, INC. | $36.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.74 | 2019-2025 | Wainua |
| Biohaven Pharmaceuticals, INC. | $29.56 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.89 | 2023 | Wavewriter Alpha Prime 16 |
| Bioventus LLC | $26.91 | 2022 | |
| Biosense Webster, INC. | $25.59 | 2020 | |
| Inspire Medical Systems, INC. | $24.46 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $24.43 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Intuitive Surgical, INC. | $24.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.14 | 2020 | |
| Antares Pharma, INC. | $21.78 | 2019 | |
| Astellas Pharma US INC | $21.25 | 2019 | |
| Novo Nordisk INC | $20.57 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $20.23 | 2019 | |
| Verity Pharmaceuticals INC. | $19.75 | 2024 | Tlando |
| Novartis Pharmaceuticals Corporation | $19.57 | 2023 | |
| Amgen INC. | $18.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.69 | 2021 | |
| Exact Sciences Corporation | $14.71 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $14.63 | 2021 | |
| Avion Pharmaceuticals | $14.27 | 2020 | |
| Philips North America LLC | $13.17 | 2022 | |
| Pfizer INC. | $13.10 | 2019 | |
| Shire North American Group INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Uhler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.